Pearce Samantha 4

What Happened

• Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals (JAZZ), received a grant of 9,782 restricted stock units (RSUs) on February 26, 2026. The award was recorded at an acquisition price of $0 (code A — grant/award).
• This was a compensation award, not an open-market purchase or sale, so there was no immediate cash exchanged or change in marketable shares.

Key Details

• Transaction date: 2026-02-26; Transaction type: Grant/Award (Form 4 code A); Price reported: $0.00.
• Shares acquired: 9,782 RSUs (each unit represents a contingent right to one ordinary share upon vesting).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: RSUs granted under the Issuer's 2011 Equity Incentive Plan. Vesting begins from a vesting commencement date of March 5, 2026 and occurs in equal annual installments over four years (1/4 on the first anniversary, then equal installments each subsequent year).
• Filing timeliness: Report filed 2026-03-02 for a 2026-02-26 transaction — filed within the two-business-day Form 4 window (timely).

Context

• RSU grants are common executive compensation and do not represent an immediate purchase or sale; value is realized only as units vest and convert to shares (or as otherwise settled).
• Because this is a grant, it does not by itself indicate buying pressure or a decision to sell shares; it reflects compensation awarded to the executive.